Modulating Serum Lipids with Berberine in Naturopathic
Clinical Practice
Volume 3 - Issue 5
Wayne Reilly*
Received: November 01, 2021 Published: November 19, 2021
*Corresponding author: Wayne Reilly, Wellness Care Australia Pty Ltd, 61 Holsworthy St Coorparoo Qld Australia
DOI: 10.32474/OAJCAM.2021.03.000171
Fulltext
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Medical intervention to reduce the risk of atherosclerosis using lipid modulating medications has been a target for reducing
cardiovascular risk for over 40 years. Lipid lowering medications, HMG-CoA reductase inhibitors (Statin’s), and more recently
PCSK9 inhibitors (PCSK9i (protein convertase subtilisin/kexin type 9 inhibitors) are now and in the future will be the main stay
therapy for reducing Atherosclerosis. However, the uncertainty of statin induced myalgia and other bad publicity via the media and
internet reports has caused many patients to opt out of statin therapy. Berberine and is quinoline alkaloid has had several clinical
trials demonstrating potential in managing cardiovascular disease risk. Berberine is a safe and natural alternative for modulating
circulating lipids including LDL-C, however possible drug interactions, due to its effects on P450 enzymes, does indicate some
caution should be exercised.
Abstract|
Introduction|
Berberine In Cardiovascular Therapy|
Conclusion|
References |